Clinical Laboratory Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Complete Blood Count, HGB/HCT Testing, Basic Metabolic Panel Testing, BUN Creatinine Testing, Electrolytes Testing, HbA1c Testing, Comprehensive Metabolic Panel Testing, Liver Panel Testing, Lipid Panel Testing, Renal Panel Testing, Cardiovascular Panel Tests), By End User (Central Laboratories, Primary Clinics), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 127.24 Billion
CAGR (2026-2031)	9.09%
Fastest Growing Segment	HbA1c Tests
Largest Market	North America
Market Size (2031)	USD 214.45 Billion

Market Overview

The Global Clinical Laboratory Tests Market will grow from USD 127.24 Billion in 2025 to USD 214.45 Billion by 2031 at a 9.09% CAGR. Clinical laboratory tests are specialized medical procedures that analyze biological specimens, such as blood, urine, and tissue, to detect, diagnose, and monitor disease states. The market is primarily driven by the rising global prevalence of chronic disorders, including diabetes and cardiovascular conditions, which necessitate frequent and accurate monitoring. Furthermore, the expanding geriatric population significantly increases the demand for diagnostic services, as older adults typically require more intensive healthcare management. These demographic and epidemiological factors serve as the foundational drivers for market growth, ensuring a sustained baseline of testing volume independent of technological market trends.

A significant challenge impeding market expansion is the critical shortage of qualified laboratory professionals, which constrains testing capacity and operational scalability. This workforce deficit creates bottlenecks that limit the ability of laboratories to process increasing sample volumes efficiently. According to the American Society for Clinical Pathology, in 2025, the vacancy rate for anatomic pathology departments was 28.5 percent. Such staffing gaps threaten to delay results and hinder the broader growth of the global clinical laboratory tests market by restricting service availability.

Key Market Drivers

Technological advancements in clinical diagnostic automation and AI integration are enhancing workflow efficiency and diagnostic precision. Laboratories are increasingly adopting artificial intelligence to process complex biological data and automate routine tasks, which is essential for managing higher testing volumes with reduced manual intervention. This technological momentum is evident in the regulatory landscape; according to the U.S. Food and Drug Administration, August 2024, in the 'Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices' list, the regulator has authorized 950 AI/ML-enabled medical devices. These innovations not only mitigate workforce shortages but also enable the deployment of more sophisticated diagnostic algorithms, ensuring laboratories can meet modern throughput demands.

The proliferation of private and independent clinical laboratory networks is driving growth through strategic consolidation. Large commercial diagnostic entities are acquiring hospital outreach programs and smaller regional labs to centralize testing and optimize supply chain costs. This trend toward large-scale network expansion involves substantial capital allocation; according to Quest Diagnostics, July 2024, in the 'Press Release', the corporation entered into a definitive agreement to acquire the Canadian provider LifeLabs for approximately CAN $1.35 billion. This consolidation ensures the continued scalability of the global market, which maintains significant revenue volumes; according to Roche, in 2024, the company's Diagnostics Division reported half-year sales of CHF 7.2 billion.

Download Free Sample Report

Key Market Challenges

The critical shortage of qualified laboratory professionals significantly hampers the growth of the Global Clinical Laboratory Tests Market by creating a hard ceiling on operational capacity. Although demand for diagnostic testing is rising due to the prevalence of chronic diseases, laboratories cannot scale their services without sufficient certified personnel to validate results and manage complex workflows. Automation enhances efficiency, yet it does not eliminate the need for skilled oversight in pre-analytical and post-analytical phases. Consequently, workforce deficits directly result in processing bottlenecks and extended turnaround times, which restricts the overall volume of tests that facilities can monetize and erodes the potential revenue gains from rising market demand.

This operational strain is further exacerbated by a shrinking workforce demographic that threatens the long-term sustainability of testing services. As experienced personnel leave the field, the capacity to train new recruits and maintain service continuity diminishes. According to the 'American Society for Clinical Pathology', in '2025', '10 out of 17 laboratory departments reported rising retirement rates compared to previous cycles'. This trend of accelerating retirements without adequate replacement deepens the staffing crisis, ensuring that service availability remains a primary constraint on market expansion.

Key Market Trends

The Increasing Utilization of At-Home Self-Collection and Sampling Kits is fundamentally reshaping patient access by decentralizing diagnostic workflows and empowering consumers to manage their health proactively. This trend moves routine screening away from traditional phlebotomy centers, allowing patients to perform non-invasive sample collection for conditions ranging from wellness markers to chronic disease monitoring in a private setting. Diagnostic providers are aggressively capitalizing on this shift by broadening their direct-to-consumer portfolios to include high-demand assays, thereby creating new revenue channels that bypass traditional physician referrals. According to Quest Diagnostics, January 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the corporation reported full-year revenues of $9.87 billion, a performance supported by the strategic expansion of its consumer-initiated test platform to include approximately 135 distinct health and wellness tests.

The Growth of Personalized Medicine and Companion Diagnostics is altering laboratory service menus as providers integrate advanced genomic and molecular testing to guide targeted therapeutic interventions. Pharmaceutical and diagnostic developers are synchronizing their pipelines to ensure that specific biomarkers can be identified to match patients with oncology and immunology treatments, thereby making high-complexity assays a standard component of clinical care. This synergy between therapeutic development and diagnostic precision is sustaining revenue streams for major industry players even as pandemic-related testing volumes decline. According to Roche, January 2025, in the '2024 Full Year Results', the company’s Diagnostics Division generated sales of CHF 14.3 billion, with the base business growing 8% driven largely by strong demand for immunodiagnostic and molecular solutions supporting advanced clinical decision-making.

Segmental Insights

The HbA1c Tests segment is anticipated to register the most rapid growth within the Global Clinical Laboratory Tests Market. This expansion is fundamentally driven by the escalating global prevalence of diabetes and the increasing emphasis on preventive healthcare management. Authoritative guidelines from organizations such as the American Diabetes Association now recommend HbA1c assays for both the diagnosis and long-term monitoring of glycemic control, which has significantly broadened their clinical utility. Consequently, laboratories are witnessing a surge in test volumes as healthcare providers prioritize these reliable metrics for early disease detection and ongoing patient management.

Regional Insights

North America maintains a leading position in the Global Clinical Laboratory Tests Market driven by the presence of established diagnostic companies and extensive healthcare infrastructure. The region faces a high burden of chronic diseases that necessitates frequent diagnostic screening and monitoring. Favorable reimbursement policies and rigorous quality oversight by agencies such as the Centers for Medicare & Medicaid Services further encourage market activity. Additionally, the growing focus on preventative care and early diagnosis in the United States and Canada supports the consistent utilization of clinical laboratory services.

Recent Developments

• In December 2025, Roche Diagnostics received approval from the U.S. Food and Drug Administration (FDA) for expanded use of its specific breast cancer diagnostic test. The regulatory clearance allowed the company’s PATHWAY anti-HER2/neu (4B5) assay to be used as a companion diagnostic to identify patients with metastatic breast cancer who express low or ultralow levels of the HER2 protein. This breakthrough enabled clinical laboratories to provide more granular prognostic information, helping oncologists identify a broader range of patients eligible for targeted antibody-drug conjugate therapies. The approval highlighted the company's focus on developing personalized diagnostic tools to improve cancer treatment outcomes.
• In September 2025, Labcorp announced a collaboration with Roche to modernize its pathology operations through the adoption of advanced digital pathology systems. The agreement involved deploying high-capacity slide scanners across Labcorp’s global network, enabling pathologists to review and interpret tissue samples using high-resolution digital images instead of traditional glass slides. The Chief Scientific Officer of Labcorp stated that this technology would facilitate remote consultations and support the future integration of artificial intelligence into diagnostic workflows. This partnership was intended to accelerate clinical decision-making and improve the precision of diagnoses for patients and biopharmaceutical clients.
• In July 2025, Thermo Fisher Scientific launched new diagnostic solutions designed to enhance efficiency and quality assurance in clinical laboratories. During the Association for Diagnostics & Laboratory Medicine conference, the company introduced LabLink360, a software platform that utilizes Sigma-metric analysis to monitor performance and streamline quality control workflows. Additionally, the company released the MAS Max quality controls, which were engineered to automate processes and reduce manual handling in high-volume testing environments. These product launches aimed to address the growing demand for faster, more accurate diagnostic results while helping laboratories manage costs and improve overall operational productivity.
• In August 2024, Quest Diagnostics completed its acquisition of LifeLabs, a leading provider of community laboratory tests in Canada, in a transaction valued at approximately CAD 1.35 billion. This strategic move expanded the company's presence internationally, allowing it to bring its diagnostic innovations and expertise to the Canadian healthcare market. The Chairman of Quest Diagnostics noted that the acquisition was designed to improve access to specialized testing and enhance patient care through combined resources. The deal included the retention of the LifeLabs brand and management team, ensuring continuity of service while leveraging new capabilities to optimize laboratory operations and data security.

Key Market Players

• Quest Diagnostics Incorporated
• Abbott Laboratories Inc.
• Cinven Group
• Laboratory Corporation of America Holdings
• Arup Laboratories Inc.
• Opko Health, Inc.
• Unilabs Diagnostics AB
• Clinical Reference Laboratory, Inc.
• Synnovis Group Llp
• Sonic Healthcare Limited

By Type	By End User	By Region
Complete Blood Count HGB/HCT Testing Basic Metabolic Panel Testing BUN Creatinine Testing Electrolytes Testing HbA1c Testing Comprehensive Metabolic Panel Testing Liver Panel Testing Lipid Panel Testing Renal Panel Testing Cardiovascular Panel Tests	Central Laboratories Primary Clinics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Clinical Laboratory Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Clinical Laboratory Tests Market, By Type:

• Complete Blood Count
• HGB/HCT Testing
• Basic Metabolic Panel Testing
• BUN Creatinine Testing
• Electrolytes Testing
• HbA1c Testing
• Comprehensive Metabolic Panel Testing
• Liver Panel Testing
• Lipid Panel Testing
• Renal Panel Testing
• Cardiovascular Panel Tests

• Clinical Laboratory Tests Market, By End User:

• Central Laboratories
• Primary Clinics

• Clinical Laboratory Tests Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE